Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 1.00 |
| ▸ | CDK4 | P11802 | 10/20 | 1.00 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | BCR | P11274 | 3/20 | 0.62 |
| ▸ | PRKCA | P17252 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.59 |
| ▸ | CDK9 | P50750 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | CDK1 | P06493 | 2/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.59 |
| ▸ | CDK7 | P50613 | 2/20 | 0.59 |
| ▸ | CCNH | P51946 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.59 |
| ▸ | CCND1 | P24385 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4613380 | 0.82 | CDK2 (0.76) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL4614974 | 0.82 | CDK2 (0.75) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL5200887 | 0.81 | CDK2 (0.69) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL5203965 | 0.81 | CDK2 (0.69) | CDK2CDK4SRCCCNT1CDK9 | |
| SCHEMBL824007 | 0.81 | ABL1 (0.84) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL4613817 | 0.79 | CDK2 (1.00) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL8293192 | 0.79 | ABL1 (0.68) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL5203806 | 0.79 | CDK2 (0.65) | CDK2CDK4GSK3BAURKAMTOR | |
| SCHEMBL4737544 | 0.79 | CDK2 (0.65) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL4734622 | 0.78 | ABL1 (0.76) | CDK2CDK4ABL1BCRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | claimed |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| EP-1373253-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | claimed |
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885ABL1 242/4885 |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885ABL1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.